1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Insulin List Prices Would Be Lowered To 2006 Levels Under House Bill

 
• By Cathy Kelly

Rebates would be prohibited and insurance coverage required without restrictions for insulin products with steep price roll-backs under bill from Reps. Diana DeGette, D-CO, and Tom Reed, R-NY.

Insulin pen
Bill Would Prohibit Rebates In Return For Lower Prices

Bipartisan legislation co-sponsored by Reps. Diana DeGette, D-CO, and Tom Reed, R-NY, seeks to drive down insulin costs by eliminating rebates for products whose list prices have been returned to 2006 levels.

The

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access

PBMs No Longer Profit From Rebates But Plans Benefit; Should Sponsors Push More For Reform?

 
• By Cathy Kelly

Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.

Why Successful Companies Are ‘Tough On Themselves’ When It Comes To HTA

 
• By Eliza Slawther

Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.